Interview Questions

The syndicate desk is the bridge between ECM origination and the equity sales force. Its job is to take a deal that ECM has won and convert it into actual investor demand at a price.

In practice, syndicate runs the order book during bookbuilding, sets and adjusts the price range based on incoming indications, advises on allocation across institutional accounts, and during pricing translates the book into a final price recommendation. They also manage the public-side communications with co-managers and the post-pricing stabilization activity (greenshoe and Reg M Rule 104 stabilizing bids).

The distinction matters: ECM origination bankers stay private-side and own the issuer relationship; syndicate sits on the public side of the wall (with controlled wall-crossing procedures for pre-launch investor meetings) and owns the investor relationship. The handoff from origination to syndicate happens once the company is launched.

The wall is the information barrier between the private-side investment-banking division (which has material non-public information about issuer clients) and the public-side equity research, sales, and trading desk (which faces investor clients). It exists to prevent MNPI from leaking into trading and research, which would create insider-trading and conflict-of-interest exposure.

ECM sits private-side and is wall-crossed: bankers know an issuer is preparing a deal before the market does. The syndicate desk straddles the wall, with controlled procedures for crossing investors over before launch. Research analysts cannot see the deal until the public announcement, and post-Global Settlement they must be independent on coverage decisions and pricing recommendations.

In practice, the wall is why ECM analysts cannot tell their friends on the trading floor about an upcoming IPO, and why research can publish on a covered name without conferring with bankers.

ECM execution requires a balance sheet and a distribution platform. To underwrite a follow-on or a bought deal, the bank takes principal risk on the shares between pricing and resale. To run a bookbuild it needs a sales force facing institutional investors. Both require committing capital and infrastructure that pure-advisory firms have deliberately avoided so they can stay conflict-free and lean.

Boutiques compete in advisory mandates (M&A, restructuring) where the deliverable is judgment, not capital. They will sometimes appear as co-advisors or co-managers on IPOs to be in the league tables and earn modest fees, but they do not lead-left bookrunner roles where balance-sheet commitment matters. Capital-markets dominance stays with bulge brackets (GS, MS, JPM, BofA, Citi, Barclays) and select large universal banks.

A typical US IPO runs roughly 6 to 9 months from kickoff to first trade, in seven phases.

1. Bake-off and mandate. The company invites banks to pitch (typically 4 to 8). Each bank presents valuation, distribution, research analyst, and aftermarket-support credentials. The company selects a lead-left bookrunner, joint bookrunners, and co-managers.

2. Organizational kickoff. The full working group (issuer, banks, issuer counsel, underwriter counsel, auditors) meets and agrees the timeline, due-diligence work plan, and S-1 drafting calendar.

3. Due diligence and S-1 drafting. Counsel and bankers conduct business, legal, financial, and industry diligence. The S-1 is drafted iteratively (typically 6 to 10 weeks) covering business, risk factors, MD&A, use of proceeds, and audited financials.

4. SEC review. The company files (publicly or confidentially under JOBS Act if an EGC). The SEC issues comments, which the company addresses through amendments. Two to four rounds of comments is normal.

5. Pre-marketing and TTW. Underwriters meet research analysts (the analyst presentation), publish pre-deal research where allowed, and management conducts testing-the-waters meetings with sophisticated institutional investors to gauge demand.

6. Launch and roadshow. Public filing of the preliminary prospectus (red herring) with a price range. Management runs the roadshow (1 to 2 weeks of investor meetings across financial centers). Bankers build the order book.

7. Pricing and trading. The night before listing, the syndicate desk and management agree the final offer price based on book demand. Shares are allocated, and the stock opens for trading the next morning. The greenshoe runs for 30 days.

Five disqualifiers in interview shorthand.

1. Sub-scale financials. US public investors generally want $100M+ in revenue with credible visibility to break-even, or a clear "story stock" thesis (biotech with phase-data catalysts). Smaller issuers struggle for liquidity and research coverage.

2. Heavy capex with no near-term cashflow visibility. Public markets can punish names that miss cashflow milestones repeatedly.

3. Concentrated customer or contract risk. A single customer at >20% of revenue creates risk-factor and earnings-volatility issues.

4. Pending litigation, regulatory, or accounting questions. SEC review will surface and amplify these.

5. Strategic-buyer optionality. If a company can clear at a premium in M&A, IPO often leaves money on the table relative to control sale, since IPOs price at a 10 to 15% discount to fair value and IPO investors do not pay control premia.

Public-ready means the company can stand up to SEC scrutiny, can produce audited financials on a public-company timeline, and has the governance infrastructure to operate as a listed issuer from day one.

Concretely, that requires: two to three years of PCAOB-audited financials, segment reporting capability, SOX 404 readiness (or path to compliance for EGCs), an independent board majority with an independent audit committee, an SEC-experienced CFO and controller, internal-controls documentation, an IR function or plan, and the systems to close books and file a 10-Q within the 40- to 45-day window.

It also means the equity story is articulable: KPIs the company can commit to publicly, financial guidance philosophy, and a credible long-term framework. Companies that go public without that get punished hard on the first earnings miss.

Lead-left is the active bookrunner, listed first on the cover of the prospectus, runs the syndicate, owns the file, and earns the largest economic split (typically 40 to 50% of the underwriting and selling concession economics on a multi-bookrunner deal). Joint bookrunners share active responsibilities and economics (typically a roughly equal split of the remaining bookrunner economics among the joint-active group). Co-managers are passive: they get league-table credit and a small fee (often 1 to 3% of the gross spread per co-manager) but do not run the book or have material allocation authority.

Lead-left selection is where the real competition happens, since a single bookrunner controls the process and accounts for the bulk of the fee pool.

The gross spread (typically 7% for sub-$100M IPOs, scaling down to 4 to 5% on multi-billion-dollar deals) is divided 20 / 20 / 60 by convention.

20% management fee: paid to the lead-left and joint bookrunners as compensation for running the deal. 20% underwriting fee: paid pro-rata to all underwriters based on their underwriting commitment, covering the principal-risk capital and out-of-pocket expenses. 60% selling concession: paid based on shares actually sold by each underwriter.

On a $500M IPO with a 7% gross spread of $35M, that is $7M management, $7M underwriting, and $21M selling concession. The lead-left typically captures 35 to 50% of total economics through a combination of larger management fee share, larger underwriting allocation, and largest selling concession. Co-managers, by contrast, may end up with $200K to $500K each on a deal of that size.

IPO diligence has four streams.

Business diligence: product, market, competition, customer concentration, KPIs, growth drivers, unit economics. Legal diligence: corporate organization, material contracts, IP, litigation, regulatory, employment matters. Financial diligence: historical financials, audit quality, accounting policies, MD&A support, segment reporting, internal controls, working-capital trends, off-balance-sheet items. Industry diligence: market sizing, growth rates, competitive positioning, regulatory trends.

The difference from M&A diligence is purpose. M&A diligence supports a buyer's decision and pricing of acquisition risk. IPO diligence supports the underwriters' Section 11 liability defense and the disclosure document. Underwriters need a documented "due-diligence defense" showing they made a reasonable investigation of all S-1 content. That drives different intensity in legal and financial diligence (often deeper than M&A) and different attention to risk-factor crafting (every diligence finding must be evaluated for risk-factor disclosure).

Underwriter participation in S-1 drafting protects the underwriters under Section 11 of the Securities Act, which imposes strict liability for material misstatements or omissions in the registration statement.

To establish a "due-diligence defense," underwriters must show they reasonably investigated the disclosure. That means underwriter counsel rewrites and challenges every section, runs negotiation sessions with management on language, and runs financial diligence sessions with the company's auditors. Underwriters also have a marketing motive: the document needs to read as a credible investment thesis to institutional investors, not just satisfy SEC disclosure rules.

Risk Factors disclose every material risk to the business that a reasonable investor would consider in making an investment decision. The purpose is twofold: investor protection (price-discovery transparency) and underwriter protection (a disclosed risk cannot later be the basis of a Section 11 claim).

Good risk factors are specific to the company, prioritized by materiality, and plain-spoken about realistic adverse scenarios. Bad risk factors are generic boilerplate that could apply to any company (the SEC routinely pushes back on this) or buried laundry-list items that obscure the most material risks.

In practice, the top three to five risk factors are heavily negotiated: bankers want them honest enough to insulate against later litigation but framed in a way that doesn't kill the equity story.

Management's Discussion and Analysis explains the financial statements through management's eyes: what drove the year-over-year change in revenue and margin, what trends are visible, what the liquidity and capital-resources picture looks like, and what known uncertainties exist.

Investors look at MD&A for three things: (1) the bridge between historical results and the equity story (do the numbers support what management is selling?), (2) the trajectory of unit economics (is gross margin expanding, is contribution margin scaling?), and (3) liquidity transparency (cash burn, runway, covenant headroom).

A strong MD&A gives investors the building blocks to model forward; a weak MD&A obscures and forces investors to discount the story.

The SEC's Division of Corporation Finance reviews the registration statement. Within roughly 30 days of initial filing, the SEC issues its first comment letter (10 to 50 comments typical) covering accounting, disclosure adequacy, and risk-factor specificity.

The company responds with an amended S-1 and a comment-response letter. The SEC issues a second comment letter (usually shorter), the company responds, and the cycle continues. Most IPOs go through two to four rounds of comments over 8 to 12 weeks.

Once the SEC has no further material comments, the company files an acceleration request and the registration statement is declared effective. Pricing happens that night.

An Emerging Growth Company (EGC) is an issuer with less than $1.235B in annual revenue (current threshold; adjusts periodically) at IPO. EGCs retain EGC status for up to 5 years post-IPO.

JOBS Act benefits: (1) confidential submission, allowing the company to file the S-1 confidentially and only go public 15 days before the road show, (2) reduced disclosure (two years of audited financials instead of three; reduced executive comp disclosure), (3) testing-the-waters communications with QIBs and IAIs before filing, (4) phased SOX 404(b) auditor attestation (deferred for up to 5 years), (5) ability to use pre-deal research from underwriters' analysts.

These benefits are why almost every venture-backed and mid-cap IPO since 2013 has been done as an EGC.

A confidential submission lets eligible issuers (EGCs, plus all foreign private issuers under SEC accommodations, plus all issuers for the first registration filing under expanded 2017 rules) file the draft S-1 with the SEC privately. The document is reviewed by the SEC and amended through the comment cycle without being visible to the public, competitors, or the press.

A public filing puts the registration statement on EDGAR and starts the public clock. From that moment, the company is in the "waiting period," gun-jumping rules tighten, and the document is fully visible to competitors and reporters.

The practical workflow: an EGC files confidentially at kickoff, runs the SEC comment cycle privately, and only makes the registration statement public at least 15 days before the start of the roadshow. That is the JOBS Act minimum to give investors time to review the document before marketing meetings.

Why issuers prefer confidential. Three reasons: (1) competitive sensitivity, since the S-1 discloses revenue concentration, customer relationships, and strategy details; (2) optionality, since a company can withdraw the filing without ever publicly announcing it tried to go public; and (3) timing flexibility, since the company can wait for a better market window before launching.

The 2017 expansion (extending confidential filing to non-EGCs for first registrations) was a meaningful pro-issuer reform that has become standard practice for nearly all US IPOs.

The analyst presentation (or "teach-in") is a closed-door session where management presents the business in detail to the underwriters' research analysts. It typically runs 3 to 4 hours and covers business model, financials, KPIs, and Q&A in much more depth than the roadshow presentation.

It is separate because of post-Global Settlement research-banking separation rules. Analysts must independently model, value, and form a view on the company. They cannot simply parrot the banker's pitch or be steered by the issuer. The teach-in is the one structured information-transfer event; afterward, analysts work independently to publish initiation reports during or after the IPO.

The output is research coverage from each underwriter, which contributes to aftermarket support and price discovery. Stronger analyst presentations produce better-informed coverage and tighter post-IPO research models.

Testing-the-waters (TTW) lets the issuer or underwriter meet with sophisticated institutional investors before the public S-1 filing, to gauge demand, refine the equity story, and identify likely anchor investors. The investor must be a Qualified Institutional Buyer (QIB) under Rule 144A or an Institutional Accredited Investor.

Originally a JOBS Act benefit reserved for EGCs (Section 5(d) of the Securities Act, 2012). The SEC adopted Rule 163B in 2019, extending TTW to all issuers regardless of size. TTW communications can be oral or written but are not "offers" within the gun-jumping framework, so they do not violate Section 5.

The discipline: TTW pitches must be consistent with later S-1 disclosure, since material discrepancies create securities-law exposure. Bankers run rigorous content review on TTW decks for that reason.

Gun-jumping is the SEC term for making "offers" to sell securities before offers are permitted under Section 5 of the Securities Act. Section 5 prohibits offers in the pre-filing period and restricts offers to permitted forms (the prospectus, free writing prospectuses, Rule 134 announcements, Rule 135 issuer notices) during the waiting period.

The SEC and courts construe "offer" broadly, to include any communication that could condition the market for the securities. So aggressive press coverage, marketing campaigns, or executive interviews timed near the filing can be gun-jumping even if no shares are formally offered.

Consequences are serious: SEC-imposed cooling-off period (delays the IPO, sometimes by months), strict liability for inadequately diligenced statements, and potential rescission rights for buyers. Bankers run a rigorous publicity blackout discipline from kickoff through roughly 10 days post-pricing for that reason, with EGCs largely exempted under JOBS Act §105(d) and the 2018 FINRA amendments.

Underwriters value the company using public-comp trading multiples (primarily) and DCF (as a cross-check). The two methods produce a fair-value range; the IPO price range is then set at a 10 to 20% discount to that fair value to attract investor demand and reduce execution risk.

Concretely: comps yield, say, an EV/Revenue range of 6 to 8x and an EV/EBITDA range of 18 to 22x. Apply to the company's forward financials, bridge from EV to equity value (subtract net debt, add IPO primary proceeds), divide by post-IPO share count. That yields a fair-value per-share range. Cut 15% off the midpoint to set the file price range, which is typically a 10 to 15% wide range (e.g., $18 to $20 per share).

The range goes into the preliminary prospectus filed at launch. It can be revised up or down during the roadshow if demand significantly differs from expectations.

Step by step.

Enterprise Value: $400M × 8 = $3.2B.

Equity Value pre-IPO: $3.2B − $50M net debt = $3.15B.

Apply 15% IPO discount: $3.15B × (1 − 0.15) = $2.6775B of pre-money equity value used for IPO pricing.

Per-share fair-discount price: $2.6775B ÷ 80M = $33.47 per share. This is the implied IPO price per share, since IPO shares price into the same equity value as existing shares.

New shares issued: $300M raise ÷ $33.47 = ~8.96M new shares.

Post-IPO shares outstanding: 80M + 8.96M = 88.96M.

Sanity check on post-money equity value: $33.47 × 88.96M = $2.978B, which equals pre-money discounted equity ($2.6775B) + primary proceeds ($300M) ≈ $2.9775B. ✓ (rounding).

At low end ($24): new shares = $600M / $24 = 25M new shares. Post-IPO share count = 150M + 25M = 175M. Implied market cap = 175M × $24 = $4.2B.

At high end ($28): new shares = $600M / $28 = 21.43M new shares. Post-IPO share count = 150M + 21.43M = 171.43M. Implied market cap = 171.43M × $28 = $4.8B.

Implication: higher pricing means fewer new shares issued (lower dilution to existing holders) for the same dollar raise. The 17% wider price range corresponds to a $600M difference in implied market cap, which is what bookbuilders manage during the roadshow. If demand is strong, pricing slides up the range, the company raises the same proceeds with less dilution, and the existing shareholders capture the upside.

Three reasons. First, IPO investors price relative to peers, not relative to intrinsic value. A buyer is choosing this stock vs other names in the sector, so the trading multiple anchors valuation. Second, IPO companies often have shorter or non-standard operating histories, making DCF projections highly assumption-sensitive (small terminal-growth changes swing the answer dramatically). Third, DCF requires a discount rate, and the right WACC for a not-yet-public company is contested.

Comps anchor the price range. DCF tells you whether the multiple-implied valuation is internally consistent with reasonable cashflow assumptions. If DCF dramatically diverges from comps, the bank investigates why before committing to the range.

Three roles.

Logistics and prep. Build the schedule, ensure top-tier accounts get one-on-one slots, brief management on the next investor before each meeting, and manage time between cities and meetings.

Coaching and content. Refine management's roadshow deck and Q&A based on feedback. If certain questions are recurring (margin trajectory, customer concentration, capital allocation), help management sharpen the answer or reframe the equity story slide.

Feedback capture and book updates. Sit in meetings, take notes on quality of demand, communicate to the syndicate desk who is interested at what price and size, and translate that into a clearing view. If the roadshow is going badly, bankers also have to deliver hard truths to management about repricing or repositioning.

Bookbuilding is the process of collecting investor orders during the roadshow at different prices and sizes, to determine the clearing price and allocation. It runs in parallel with the roadshow (typically 1 to 2 weeks).

After each investor meeting, the institutional sales force on the public side asks investors for an "indication of interest" (IOI): how many shares they want and at what price. The syndicate desk aggregates IOIs across all underwriters into a consolidated order book.

By end of the roadshow, the book typically shows the demand curve: how many shares are wanted at the top of the range, the midpoint, and the bottom. The desk evaluates the cover ratio (oversubscription level: a "10x covered book" means 10x more demand than shares offered), the quality of demand (long-only vs hedge fund vs retail), and price sensitivity (demand elasticity).

Final pricing happens on the night before listing, based on the book.

Cover ratio = total demand at a given price ÷ shares being offered. A 10x covered book at the high end of the range means investors have placed orders for 10x more shares than the deal size at that price.

Cover matters because it drives pricing power. Highly oversubscribed books (>10x on quality demand) often price at or above the high end and trade up on day one. Modestly covered books (2 to 4x) tend to price at the midpoint with neutral aftermarket. Undercovered books (<1.5x) tend to price below the range or get pulled.

Cover ratio is also the input to allocation: when a book is 10x covered, only 10% of orders can be filled, so the syndicate desk has to choose which investors get how much. Quality of demand (long-only > sovereign wealth > index-linked > hedge fund > retail) drives those decisions.

On the night before listing, the syndicate desk and lead-left run a pricing call with management and the board.

The desk presents the final book: total demand by price level, demand quality breakdown, peer-comp positioning, and a price recommendation. Management and board decide the final price, typically in consultation with the desk. The decision balances several tensions: maximizing proceeds for the company, leaving enough on the table for a positive first-day trade, rewarding key anchor investors with allocation at attractive economics, and honoring the price-range guidance given to investors during the roadshow.

If the book supports it, deals price at the high end (or above the range, in which case the SEC requires a free-writing prospectus with revised pricing). If demand is weak, deals price at the low end or below. After the call, the underwriting agreement is signed, allocations are set, and trading opens the next morning.

Allocation is discretionary, decided by the syndicate desk in consultation with the issuer. There is no "first come, first served" rule.

The standard allocation hierarchy: (1) anchor and cornerstone investors if any (locked-in pre-deal commitments); (2) high-quality long-only mutual funds and pension funds (Fidelity, Wellington, T. Rowe, Capital, Vanguard) get the largest discretionary allocations; (3) sovereign wealth funds (GIC, Temasek, ADIA, QIA) for size and stability; (4) high-conviction hedge funds with sector expertise; (5) other institutional accounts; and (6) retail through participating brokers, typically capped at 10 to 15% of the deal.

Within these tiers, the desk weighs three factors: size of order, price sensitivity (strike or scaled vs limit), and expected hold pattern (will this investor still own the stock in 6 months?).

Long-only investors (mutual funds, pension funds) typically hold for fundamental reasons over multi-year horizons. They contribute to aftermarket stability, tighter trading spreads, and lower volatility post-IPO, which are exactly what the issuer wants.

Hedge funds (especially fast-money and event-driven) flip allocations on day one, which creates first-day selling pressure, depresses the aftermarket, and can pressure the stock below the offer price. They also do not tend to support follow-ons or build long-term positions.

The exception is sector-expert hedge funds (long/short equity funds with deep sector knowledge) who can support price discovery and provide a price-sensitive "smart money" anchor. Banks selectively allocate to those, but heavily under-allocate fast-money flippers.

The greenshoe (formally the "overallotment option") gives underwriters the right to sell up to 15% additional shares beyond the base offering, exercisable for 30 days after pricing. The name comes from Green Shoe Manufacturing, the first issuer to use the structure.

Why it exists: it creates a price-stabilization mechanism that is costless to the issuer. The underwriters create a synthetic short position by selling 115% of the deal at pricing, then have a choice in the 30 days post-listing.

If the stock trades above the offer price, the underwriters exercise the greenshoe and buy the additional 15% from the company at the offer price, delivering them to investors. This generates additional proceeds for the issuer and additional underwriting fees.

If the stock trades below the offer price, the underwriters cover their 15% short by buying in the open market (at prices below the offer). This creates buying pressure that supports the price, while the underwriters keep the spread (offer price minus market price). The issuer is unaffected; the underwriters have hedged their stabilization exposure.

Base deal: 100M shares × $20 = $2.0B to issuer (less gross spread).

Greenshoe shares: 15M shares (15% of 100M) sold short by underwriters at $20 = $300M of additional shares sold to investors.

Stock trades to $17. Underwriters cover the 15M-share short by buying in the open market at $17 average. Cost: 15M × $17 = $255M.

Underwriters' P&L on stabilization: $300M (proceeds from short sale at offer) − $255M (cost to cover at $17) = $45M gross, before expenses.

Issuer: unchanged. Receives only the base $2.0B in proceeds; greenshoe is not exercised against the issuer because the underwriters covered in the market instead. No additional shares issued, no additional dilution.

Practical effect: the 15M-share buy-in supported the stock during the 30-day period (without it, the stock would likely have traded lower). The underwriters earned $45M on stabilization, which compensates for the principal risk of standing behind the deal.

Base deal: 100M shares × $20 = $2.0B to issuer (less spread).

Greenshoe shares: 15M shares sold short at $20 = $300M.

Stock trades to $24. Underwriters cannot profitably cover their short in the market (would cost $360M). They exercise the greenshoe instead, buying 15M shares from the issuer at the offer price of $20 = $300M.

Issuer: receives an additional $300M in proceeds (ignoring spread on greenshoe shares). Also issues 15M more shares (additional dilution beyond the base deal).

Underwriters: flat on the greenshoe (sold at $20, bought from issuer at $20 = zero P&L). They earn the gross spread on the additional $300M of greenshoe-related proceeds.

Practical effect: when a stock trades up, the greenshoe lets the issuer raise more capital at the offer price, dilutes existing shareholders by another 15%, and rewards the underwriters with additional fees. The 30-day period exists so the desk can wait and see how the stock prints before exercising.

Stocks frequently dip into lockup expiration as the market anticipates supply. The typical pattern: 5 to 15% drift down in the 2 to 4 weeks before expiry, modest selling pressure on the day, and then recovery if fundamentals are intact.

The size of the move depends on (1) how much locked-up stock will become free (50% of the float entering the market is dramatically different from 5%), (2) likelihood of insider selling (sponsors will sell; founders often will not), (3) the stock's performance since IPO (deep losers see less selling because insiders won't sell at depressed prices), and (4) whether secondary follow-on offerings are pre-arranged.

Banks frequently structure orderly secondary follow-ons or block trades coincident with lockup expiry, so insiders sell into a single distributed transaction rather than dribbling shares into the market.

Pre-IPO holder share count at IPO: 100M.

At 180-day expiry: 60% × 100M = 60M shares sold at $52 = $3.12B monetized.

Remaining locked or held at 6 months: 40M shares.

At 12 months: 25% × 100M = 25M shares sold via blocks at $48 = $1.2B monetized.

Remaining held: 40M − 25M = 15M shares.

Total monetized to date: $3.12B + $1.2B = $4.32B.

Implied gain vs IPO price: insiders held shares worth $35 × 85M sold = $2.975B at IPO price; sold for $4.32B, a $1.345B premium above IPO-price value.

Of remaining 15M shares at current $55 price: worth $825M at current market.

Total realized + unrealized capital from pre-IPO holdings: $4.32B realized + $0.825B unrealized = $5.145B, vs IPO-price value of $35 × 100M = $3.5B. Insiders captured a 47% premium on the position by selling into the post-IPO rally.

Under FINRA Rule 2241 (formerly NASD Rule 2711) and the JOBS Act, EGCs allow research from underwriters at any time, including immediately post-IPO with no waiting period. For non-EGCs, the post-IPO research blackout is 10 days for managing underwriters of an IPO.

Research initiation matters because it provides the first independent fundamental coverage of the stock by the analysts who know it best. A "buy" rating from the lead-left analyst with an above-IPO price target signals analyst conviction and supports the aftermarket. Coverage by multiple underwriter analysts, all initiating with positive ratings, reinforces the equity story and creates a sell-side narrative for portfolio managers to lean on.

Coverage is independent (post-Global Settlement separation rules), so analysts cannot be paid based on banking revenue and cannot be steered by bankers. But the analyst presentation during the IPO process gives them a deep informational base from which to write strong initiations.

Traditional IPOs solve one shape of problem: a company with two to three years of audited financials, a clean equity story, and willingness to wait 6 to 9 months for SEC review wants public capital and a public listing.

Alternatives exist for companies that don't fit that mold or want to avoid parts of the process. SPACs offer speed (3 to 6 months from announcement to close), pricing certainty (negotiated valuation rather than book-built), and access for companies with shorter financial track records or non-standard businesses. Direct listings allow already-well-known companies to go public without the IPO discount and without dilution. Reverse mergers allow smaller or restricted companies to access public markets at lower cost. Dual-track and triple-track processes preserve optionality between IPO, M&A, and continuation-vehicle exits.

Each alternative has tradeoffs (sponsor promote dilution, lower research coverage, lower aftermarket liquidity, listing-venue limitations) but each fills a specific gap that traditional IPOs cannot cover.

The promote is the 20% founder-share stake the SPAC sponsor receives at IPO for $25K. If the SPAC raises $200M and the deal closes, the sponsor's $25K stake converts into roughly $50M of post-merger equity. The sponsor takes on real risk (forfeiture if no deal closes; reputational risk on sponsorship) but the upside math is asymmetric.

It is controversial because the promote is dilutive to public shareholders. After a de-SPAC, public shareholders (and the target company's existing owners) bear the dilution cost of the sponsor's 20%, which has been called "free shares paid by everyone else." Yale Journal on Regulation has argued that the right disclosure metric is "net cash per share," which makes promote dilution explicit: a $10 IPO with 20% promote and zero redemptions starts with $8 of cash backing per public share.

In recent deals, sponsors increasingly forfeit or vest portions of the promote as part of the de-SPAC negotiation, to align with the target and reduce dilution.

SPAC IPOs typically sell units consisting of one share plus a fractional warrant (often 1/3 or 1/2 warrant per share). Warrants are 5-year out-of-the-money call options on the post-merger stock, with a strike price of $11.50 (15% above the $10 IPO price).

Warrants exist to compensate IPO investors for the time-value of capital sitting in trust at low Treasury yields. Investors get to redeem at IPO IPO price ($10) and keep the warrant for free, creating an asymmetric payoff: capital protection plus equity-call upside.

Sponsors also receive private-placement warrants (typically purchased for $1.00 to $1.50 each) to align with the deal closing.

After de-SPAC, public warrants typically trade based on stock price (Black-Scholes intrinsic + time value). Warrants are dilutive when in-the-money, and the "warrant overhang" is a recognized post-de-SPAC drag on stock prices.

A SPAC IPO has no operating company to value. The pitch is the sponsor's track record and target thesis. SEC review of an S-1 for a shell company is shorter (4 to 8 weeks vs 12+ for an operating company). There is no equity story to build because there is no business yet.

Marketing focuses on the sponsor team and target sector thesis. Demand comes primarily from "SPAC arbs": hedge funds that buy units, hold the share for the trust-redemption floor (locked at $10 plus interest), and trade the warrant separately. Long-only investors are a smaller share of SPAC IPO demand than a normal IPO.

Pricing is fixed at $10 by convention. The "deal" is the future de-SPAC, not the IPO itself.

The de-SPAC is the business combination between SPAC and target.

1. LOI and due diligence. Sponsor and target sign a letter of intent and run formal diligence (typically 4 to 8 weeks).

2. Definitive merger agreement. Negotiated terms include valuation, consideration mix (cash + stock), sponsor promote treatment (full vs partial forfeiture), minimum cash conditions, board composition, and PIPE financing.

3. Public announcement. Markets see the deal for the first time. A presentation deck and forward-looking financial projections are typically published.

4. S-4 registration statement. SEC review of merger proxy and registration of new shares. This includes target audited financials and detailed disclosure. Typically 12 to 16 weeks of SEC review.

5. PIPE financing. Private placement of new shares (typically at $10 or below) to backstop the deal against redemptions and provide growth capital.

6. Public shareholder vote and redemption. SPAC public holders vote to approve and separately decide whether to redeem at the trust value (typically $10+ accrued interest).

7. Closing. Funds flow: trust + PIPE + any debt = consideration to target. Combined company emerges with new ticker, new board, new business.

A PIPE is a private placement of new shares concurrent with the de-SPAC closing, typically priced at the $10 SPAC IPO price (or below).

It serves two purposes. Backstop redemption risk. If 80% of public SPAC holders redeem, the SPAC loses 80% of its trust capital. PIPE investors commit money irrespective of redemption, ensuring the combined company has enough capital to close and operate. Validate valuation. PIPE participants (institutions, mutual funds, strategic investors) due-diligence the target and price the deal, which is a market-validation signal that helps support the public-side narrative.

PIPE investors typically include a mix of long-only mutual funds, hedge funds, sovereign wealth, and strategic investors. They do not have redemption rights, so their commitment is a hard backstop.

The SEC adopted final rules in January 2024 aimed at aligning SPAC and traditional IPO investor protections. Three biggest changes:

(1) Underwriter liability. The rules clarified that financial advisors and underwriters in de-SPAC transactions can be considered statutory underwriters under Section 11, exposing them to strict-liability disclosure standards. This significantly raised the legal exposure for banks advising on de-SPACs and led several banks (Goldman, Citi) to deprioritize the business.

(2) Restrictions on forward-looking projections. SPAC merger proxies historically used long-dated forward projections (5- to 10-year revenue and earnings forecasts) more aggressively than traditional IPO documents. The 2024 rules removed the safe harbor under PSLRA for forward-looking statements in de-SPAC transactions, making projections subject to securities-law liability if not adequately supported.

(3) Enhanced disclosure. Sponsor compensation, dilution risk, sources and uses of cash, conflicts of interest, and target valuation methodology must be disclosed in plain English in registration statements.

Effect: the 2024 rules dramatically narrowed the SPAC market vs the 2020-2021 boom. Quality SPACs continue to launch but volume is a fraction of peak.

Traditional IPO is preferred when: company has two to three years of clean audited financials, business model is well-understood and easy to comp, market window is open and demand is constructive, and management can absorb a 6 to 9 month process. The IPO discount is the cost; full price discovery and broad institutional ownership are the benefits.

SPAC is preferred when: company has shorter financials or non-standard accounting, business is harder to comp (early-stage, novel category), management wants pricing certainty (negotiated valuation), or market window is uncertain and the company wants to lock in valuation. Sponsor promote dilution and post-deal warrant overhang are the costs; speed and pricing certainty are the benefits.

Direct listing is preferred when: company is already well-known to public investors (Spotify, Slack, Coinbase pattern), insiders want liquidity but the company doesn't need primary capital, and the company wants to avoid IPO discount and underwriter allocation discretion.

After 2022 the SPAC market shrank dramatically; for most issuers, traditional IPO or direct listing is now the default and SPAC is reserved for cases where its specific advantages clearly apply.

Traditional IPO direct costs: gross spread of 5 to 7% of proceeds plus $3M to $7M of legal, audit, and printing fees. Total all-in: 6 to 8% of proceeds.

SPAC direct costs from target's perspective: SPAC underwriting fees were paid at SPAC IPO (5.5% deferred to de-SPAC closing), plus SPAC sponsor's 20% promote dilution, plus PIPE underwriting fees (typically 4 to 5%), plus advisory fees, plus de-SPAC legal and audit costs. Total all-in: 15 to 25% dilution-equivalent for the target.

The headline that SPACs are "cheaper" is misleading. Direct cash costs may be lower, but the 20% promote is a transfer of value from new shareholders to the sponsor that does not appear in cash-fee accounting. Net of promote dilution, SPACs are typically more expensive than IPOs unless the SPAC's pricing certainty or speed delivers a real value beyond what a traditional IPO would have produced.

A direct listing is a method of going public where a company lists its existing shares on an exchange without an underwritten primary offering. Existing shareholders (founders, employees, sponsors) sell shares directly into the market at the opening trade.

Differences from a traditional IPO:

No primary capital raise (originally; the NYSE later approved primary direct listings, but they are rare). No underwriter allocation: shares trade in an open auction with no banker discretion. No price-stabilization mechanism: no greenshoe, no underwriter market support. No IPO discount: the market clears at fundamental value, so insiders capture the full value, but there is no "IPO pop" for new buyers. No lockup (in the original Spotify and Slack format), since insiders sell directly into the listing.

Direct listings work for well-known companies with broad public awareness, where price discovery doesn't require a roadshow and book-build to bridge information gaps. They don't work for lesser-known companies, where the absence of a roadshow means buyers won't show up.

Both had three characteristics that made direct listing fit better than IPO. (1) Broad public awareness. Both consumer-facing brands with well-understood business models, removing the roadshow's information-distribution function. (2) No primary capital need. Both had ample cash; the listing was for liquidity, not fundraising. Eliminating the primary-issuance dilution and gross spread saved meaningful value. (3) Strong existing trading-market signals. Both had deep secondary-market trading of private shares before listing, so there was real price discovery already happening. The direct listing simply formalized that on the public market.

Both also explicitly rejected the IPO discount: management wanted insiders to capture the full value of their stakes rather than leave 10 to 20% on the table for IPO investors. The Slack direct listing in particular was a public statement against the IPO underpricing convention.

A reverse merger is a transaction where a private operating company merges with an existing public shell company, with the operating company's shareholders ending up with control of the combined entity. Effectively, the private company takes over the public listing.

It differs from a SPAC reverse merger because the public shell is not a SPAC. It is typically a previously operating company that is now defunct (a "former operating company" shell) or a newly registered shell created by a sponsor.

It is used when: company is too small for a traditional IPO (<$40M valuation often disqualifies for NYSE/Nasdaq IPO underwriting), wants to access public markets at low cost, is in a sector where IPO windows are difficult, or needs rapid public-listing for strategic reasons.

The 2024-style scrutiny: the SEC has rules requiring that companies emerging from non-SPAC reverse mergers cannot use Form S-3 (the streamlined shelf) until 12 months post-merger, must trade on OTC for at least a year before exchange listing, must trade above $4 for 30 of 60 consecutive days before listing, and face heightened ongoing disclosure. Stock exchanges treat these companies more cautiously than SPAC merger products.

Pros: maximum optionality (you keep both exits live until the last responsible moment), competitive tension that improves both outcomes (a credible IPO threat improves M&A bids; a credible M&A threat reduces IPO discount), and price discovery from both processes.

Cons: double the cost (legal, banker, and advisor fees on both tracks; typically 20 to 40% more than a single-track process), management bandwidth strain (running two processes is intense and risks signal leakage to either set of counterparties), and the perception risk that "the company is in play," which can hurt customer and employee morale.

Dual-tracks are typically reserved for PE-backed sponsors who want to maximize exit value and don't have strategic constraints, and for companies in sectors with both natural strategic buyers and IPO-receptive markets (mid-cap healthcare, tech, consumer brands).

Triple-track is a sponsor exit process that runs three paths in parallel, expanding the traditional IPO-versus-M&A dual-track framework. The term carries multiple meanings in industry usage. The most common modern definition adds a GP-led continuation vehicle (CV) as the third track alongside IPO and M&A. An older definition adds a refinancing or dividend recap instead, with the third track returning capital to LPs through a financing transaction rather than a sale.

Under the CV definition, the existing PE fund sells the portfolio company into a newly-raised continuation fund managed by the same GP, with new LPs (often secondaries-focused funds like Lexington, ICG, AlpInvest, Coller) providing the capital. Legacy LPs choose between cashing out or rolling into the CV. CVs have grown rapidly since 2020, accounting for nearly 19 percent of sponsor-backed exit volume in 2025.

The framework only applies to sponsor-held assets. A different PE firm acquiring the company through a standard sale process is not a separate track in this framework, since that buyer lives inside the M&A path alongside strategic acquirers. The three tracks under the CV variant engage three structurally different buyer universes: public-market investors (IPO), strategic and financial buyers (M&A), and secondaries LPs together with the existing GP (CV).

Day 0 (announcement): company files a prospectus supplement and a press release at market close. Stock often trades down 3 to 8% on the announcement (the "pricing-in" of dilution).

Day 1 to Day 2: management roadshow. Typically morning calls and lunches with key institutional investors in NYC, sometimes Boston and West Coast. Concurrent bookbuild by the syndicate desk.

Pricing (end of Day 2 or Day 3): lead bookrunner and management agree pricing based on book. Pricing typically at a 3 to 8% discount to the closing price on the day of pricing.

T+1 settlement (since May 28, 2024): trades settle, shares delivered.

The 1- to 3-day window is the price-risk window. If the stock drops materially during marketing, the desk and issuer renegotiate the file price or pull the deal.

Pre-announcement market cap: 200M × $80 = $16B.

After 5% announcement drop: stock at $76, market cap $15.2B.

On pricing day, close at $74. File at 5% discount: $74 × (1 − 0.05) = $70.30 per share.

Shares issued: $1B / $70.30 = 14.22M shares.

Post-deal share count: 200M + 14.22M = 214.22M.

Dilution to existing holders: 14.22M / 200M = 7.1%.

Implied fully-distributed market cap: 214.22M × $70.30 = $15.06B ≈ pre-deal market cap less the $0.14B that flowed to issuance discount + market reaction.

Insight: the issuer raised $1B with 7.1% dilution but at a $70.30 file price, well below the $80 pre-announcement price. If the announcement and discount mechanics had not pressed the stock, the same $1B raised at $80 would have implied 12.5M new shares (6.25% dilution). The 0.85% extra dilution is the price of a marketed deal vs theoretical at-market issuance.

A bought deal is a follow-on where the underwriter purchases the entire offering from the issuer at a fixed price after market close, then sells the shares overnight to institutional investors before market open the next day.

Mechanics: typically initiated as a competitive process where the issuer (or its lead bank) approaches multiple banks for bids on a wall-crossed basis. The winning bidder commits principal capital to buy all shares at a fixed price (typically a 3 to 7% discount to last trade). The underwriter then has the overnight window to "sell down" to institutional buyers and reduce its position before markets open.

Used for fast execution, small-to-mid size deals (typically under $1B, sometimes larger), and when the issuer wants pricing certainty without market-timing risk. Common for sponsor sell-downs and quick capital raises.

Principal price risk. In a bought deal, the underwriter buys the shares at a fixed price and then has to resell. If overnight demand comes in below the bought price, the underwriter eats the difference. If markets gap down before the resale completes, the loss compounds.

In a marketed follow-on, the underwriter is on a "best efforts" or agency basis: the bank takes orders, books demand, and prices at the level the book clears. If demand is weak, the deal prices lower or gets pulled, but the underwriter doesn't carry shares on its balance sheet at risk.

This is why bought deals trade at wider discounts than marketed follow-ons: the underwriter prices in compensation for principal risk.

A block trade is a single private negotiated transaction in which a large quantity of shares moves from a seller (typically a sponsor or insider) to one or more buyers, usually with no marketing whatsoever.

Differences from a bought deal:

No marketing. Bought deals get an overnight wall-cross to institutions; blocks are typically negotiated bilaterally between seller and one or two key institutional buyers without a broader bookbuild. Speed. Blocks can execute in minutes after a wall-cross to a willing buyer. Discount. Block trades often price at wider discounts (6 to 10%) because there is no marketing-driven demand discovery. Filing. Blocks may be done off-market via a Rule 144 sale or filed via a prospectus supplement off shelf depending on whether the seller is an affiliate.

Use blocks for fast, discrete sponsor sell-downs where speed and confidentiality matter more than price optimization.

Three drivers. Size and concentration. A block sells a large quantity in one go; ATMs dribble shares at market over weeks. If the sponsor needs $300M of liquidity in one day, a block fits and an ATM does not. Confidentiality. Block negotiations happen privately; the trade prints once executed. Marketed follow-ons require public filing and announcement, which signals dilution and pressures the stock during the marketing window. Volume constraints. ATMs are limited by practical execution constraints (typically 10 to 15% of ADV) under the sales agreement, with Reg M Rule 102 distribution limits applicable; large positions can take quarters to clear via ATM, vs same-day via block.

The trade-off is price: blocks accept a wider discount than ATMs (which clear at market) and often wider than marketed follow-ons.

ATM works best when: deal size is small enough to fit within daily ADV constraints (otherwise it takes too long to clear), company values flexibility on timing and price, the equity tape is volatile and the company doesn't want to commit to a single pricing event, and the company is comfortable with continuous dribble rather than a defined raise.

Marketed follow-on or block is better when: size is large relative to ADV, the company needs the capital quickly for a defined use, or the issuer wants pricing certainty.

REIT and biotech issuers are heavy ATM users because their capital needs are recurring and incremental. Industrials and consumer issuers more often choose discrete follow-ons sized to specific events (acquisitions, capex programs).

A rights offering gives existing shareholders the right (but not obligation) to buy new shares at a discount to the current market price, in proportion to their existing ownership. The discount is typically 20 to 40%, much wider than a marketed follow-on.

Mechanics: company announces the offering with a record date, subscription ratio (e.g., 1 new share for every 5 held), subscription price, and exercise window (typically 2 to 4 weeks). On record date, eligible holders receive transferable rights, which trade on the exchange during the exercise period. Holders can exercise the rights to buy new shares at the subscription price, sell the rights in the market, or let them lapse.

Oversubscription privilege: holders who exercise their basic rights typically get the option to buy any unsubscribed shares pro-rata, ensuring the deal can clear even if some holders don't participate.

New shares issued: 100M × (1/4) = 25M new shares.

Total post-rights shares: 100M + 25M = 125M.

Capital raised: 25M × $14 = $350M.

TERP (Theoretical Ex-Rights Price): TERP = [(existing shares × current price) + (new shares × subscription price)] / total shares post-rights TERP = [(100M × $20) + (25M × $14)] / 125M TERP = [$2,000M + $350M] / 125M TERP = $2,350M / 125M = $18.80 per share.

Value of one right: in a 1-for-4 offering, each existing share gets one right, and 4 rights + $14 entitle the holder to 1 new share worth $18.80. So the rights bundle is worth TERP − subscription = $18.80 − $14.00 = $4.80, and each individual right is worth $4.80 / 4 = $1.20 per right.

Sanity check: A holder of 4 existing shares (worth 4 × $20 = $80) gets 4 rights. Exercising those rights costs $14 for 1 new share. Post-rights, they own 5 shares × $18.80 = $94. Their net position: $94 − $14 (paid) = $80. ✓ Wealth is preserved if they exercise.

If they don't exercise and don't sell the rights, they end up with 4 shares × $18.80 = $75.20, which is $4.80 less than the original $80. That $4.80 lost is the value of all 4 rights, confirming $1.20 per right. ✓

An Accelerated Share Repurchase (ASR) is a structured share buyback executed through an investment bank, where the company commits a defined cash amount upfront, the bank delivers a large block of shares immediately (typically 80 to 90% of the expected total), and the bank then covers its short position by buying shares in the open market over a defined window (typically 3 to 6 months).

The final settlement adjusts based on the volume-weighted average price (VWAP) of the stock during the buyback window. If VWAP is below the initial reference price, the company gets additional shares (or money back). If VWAP is above, the company pays more (or delivers fewer additional shares).

ASRs let companies execute large buybacks in a single accounting event (immediate share-count reduction, immediate EPS accretion) rather than stretching out a regular open-market repurchase over months.

Three reasons. Speed and certainty of share-count reduction. ASR delivers the bulk of shares immediately, locking in EPS accretion without waiting for daily Rule 10b-18 volume limits to bring the buyback to completion. Signaling. A large committed ASR signals management confidence in the stock and capital-allocation discipline. Pricing efficiency. The bank's trading desk can typically execute the buyback at or below VWAP using sophisticated execution algorithms, often outperforming what the company could achieve directly.

The trade-off: ASRs have a defined cash commitment with limited flexibility, vs an open-market program which the company can pause, accelerate, or terminate. ASRs also have small banker fees (typically a few bps of notional), which open-market programs don't.

Sponsors typically can't sell at IPO (most of their position is locked up) and need to exit over multiple post-lockup transactions. Common patterns:

Lockup-expiry secondary follow-on: Sponsor and company coordinate a marketed secondary follow-on around lockup expiry, selling 25 to 50% of the sponsor's stake in one pricing event. Often done concurrently with a primary raise or alone.

Subsequent block trades: As the position reduces, sponsors execute smaller block trades quarterly, distributing sell-downs over 12 to 24 months. Each block clears 5 to 15% of the remaining position.

Distribution in kind to LPs: Some PE funds distribute public shares directly to their LPs rather than selling. Each LP can then sell on their own schedule. This avoids price-impact concentration and gives the fund a clean closeout, but most LPs (mutual funds, pensions) sell soon after distribution.

The choice between these depends on size, market depth, urgency, and the PE fund's NAV-management preferences.

S-3 is the short-form registration statement for US domestic seasoned issuers. F-3 is the equivalent for foreign private issuers.

To be eligible for S-3, an issuer must (among other things) have a public float of at least $75M of voting and non-voting common equity held by non-affiliates, have been a reporting company for at least 12 months, and be timely on filings.

A Well-Known Seasoned Issuer (WKSI) is a higher tier: public float of at least $700M, or having issued at least $1B of registered non-convertible securities in the prior three years. WKSIs can use automatic shelf registration, which becomes effective upon filing (no SEC review wait), and benefit from streamlined disclosure.

For a large issuer, WKSI status means a follow-on or bond deal can launch and price the same day a draft prospectus is finalized, with no SEC delay.

Regulation M is the SEC's anti-manipulation rule set governing securities offerings. It restricts distribution participants (underwriters, broker-dealers, the issuer, selling shareholders, and their affiliates) from bidding on, purchasing, or attempting to induce others to purchase the offered security during a defined "restricted period" before and around pricing.

It exists to prevent the kind of pump-and-dump scenario where the issuer or underwriter could artificially support the secondary market just before pricing to inflate the deal price.

Key rules:

Rule 101: restrictions on distribution participants other than the issuer. Rule 102: restrictions on the issuer and selling stockholders. Rule 104: safe harbor for stabilizing bids by underwriters (the rule that permits IPO price stabilization). Rule 105: prohibits short selling in the 5 days before pricing of a follow-on offering, then covering with deal shares (the "pre-deal short squeeze" trade).

Restricted-period length depends on float and ADV: typically 1 to 5 days before pricing, depending on issuer size.

The choice depends on size, urgency, market conditions, and issuer characteristics.

Marketed follow-on if: $400M is large vs ADV (need broad bookbuild to clear), management is willing to roadshow, current tape is constructive, and pricing optimization (tighter discount) matters more than execution speed. Typical execution: 1 to 3 days.

Overnight bought deal if: speed matters more than pricing (e.g., funding an acquisition or capital event with a defined deadline), there is one or more banks willing to commit principal, and the issuer is a well-known stock with strong demand profile. Typical execution: same night, deeper discount (5 to 7%).

ATM if: the company doesn't need all $400M immediately and prefers dribble execution at market over weeks (typically would take 4 to 12 weeks for $400M depending on ADV). Lowest fees and tightest pricing, but slowest.

Rights offering if: the issuer wants to give existing shareholders pro-rata participation rights (common in Europe), or in a distressed situation where deep discount is needed and a backstop is available. Rare in US for healthy companies.

In practice, marketed follow-on or bought deal dominate for healthy US issuers raising $400M. The decision often comes down to the issuer's preference for pricing optimization (marketed) vs execution certainty (bought).

Convertibles solve a specific capital-structure trade-off.

Vs straight debt: the embedded conversion option lets the issuer cut the coupon by 200 to 400+ bps below comparable straight-debt rates. The issuer is effectively selling investors equity upside in exchange for lower interest expense.

Vs straight equity: the equity is issued at a 20 to 40% premium to current stock price (the conversion price). If the stock never rises above the conversion price, no shares are ever issued and the issuer just pays a low-coupon bond. If the stock rises moderately, the issuer takes some dilution but at a much higher price than a follow-on would have achieved.

The classic use case: a high-growth company that believes its stock is undervalued and doesn't want to issue equity at the current price. A convert lets them lock in equity issuance at a higher price contingent on the stock rising. If management is right and the stock rallies, the convert is dilutive but at a premium. If management is wrong and the stock stays flat, they paid a low coupon for cheap debt.

The investor side: convertible buyers want bond-floor downside protection plus equity-call upside. Their accepted compensation is the 20 to 40% conversion premium and the lower coupon.

Treatment depends on whether the convertible is in or out of the money.

Out-of-the-money convertible (stock price below conversion price): treat as debt at face value. Add to debt in the EV bridge.

In-the-money convertible (stock price above conversion price): treat as equity through the diluted share count. Use the if-converted method: add the conversion shares to the diluted share count and exclude the convertible's face value from debt. Do not double-count.

A common interview pitfall: candidates either include the convertible in both debt and dilution, or in neither. The right answer is to apply if-converted treatment based on whether conversion is economic for the holder.

For mandatory convertibles (which always convert), always treat as equity through dilution regardless of stock price.

Conversion price: $40 × (1 + 0.30) = $52 per share.

Conversion ratio: $1,000 / $52 = 19.23 shares per bond.

Coupon income over 5 years: $1,000 × 1.5% × 5 = $75 total coupon (vs $1,000 × 5% × 5 = $250 for straight debt). The bondholder is foregoing $175 of interest income over 5 years for the conversion option.

Breakeven stock price (the price at which 19.23 shares equal the lost interest plus par recovery): The convert holder gets $1,000 par back plus $75 coupons = $1,075 total cash if no conversion. The straight-debt holder gets $1,000 par back plus $250 coupons = $1,250 total cash. For the convert to break even via conversion, conversion proceeds must equal $1,250. Required share price: $1,250 / 19.23 = $65 per share.

That is 62.5% above the issue stock price of $40, or 25% above the conversion price of $52. The convert holder needs the stock to rally significantly above the conversion price to outperform straight debt. In exchange, the convert holder has bond-floor downside protection if the stock falls.

Conversion ratio: $1,000 / $40 = 25 shares per bond.

Parity (conversion value): stock price × conversion ratio = $50 × 25 = $1,250 per bond.

Conversion premium at $1,300 bond price: (Bond price − Parity) / Parity = ($1,300 − $1,250) / $1,250 = 4% premium.

Interpretation: the bond trades at $1,300, which is 4% above what the underlying shares are worth ($1,250). That 4% premium is the value the market assigns to the embedded option (bond-floor protection plus continued upside) above the immediate conversion value. A bond trading at parity (zero premium) means the option value is being squeezed; a bond trading at a higher premium means the option is more valuable (e.g., higher implied volatility, more time to expiry, more out-of-the-money path).

Conversion price: $50 × 1.30 = $65 per share.

Conversion ratio per bond: $1,000 / $65 = 15.38 shares per bond.

Total bonds outstanding: $1B / $1,000 = 1M bonds.

Total conversion shares if all convert: 1M × 15.38 = 15.38M shares.

Post-conversion share count: 200M + 15.38M = 215.38M.

Dilution percentage: 15.38M / 200M = 7.7% dilution.

Value transfer: at $90 stock, the conversion shares are worth 15.38M × $90 = $1.384B. Bondholders gave up $1B of par value and received $1.384B of stock, capturing $384M of upside above par.

Equivalent if instead of converting: bondholders held to maturity. They'd receive $1B par + 5 × 1% × $1B coupons = $1.05B. By converting at $90, they capture $1.384B − $1.05B = $334M more than holding the bond.

For the issuer: vs straight equity issuance at $50 (when convertible was issued), the issuer effectively issued equity at $65 (the conversion price), reducing dilution. If the company had done a $1B follow-on at $50 instead, it would have issued 20M shares (10% dilution). With the convertible, only 15.38M shares are issued (7.7% dilution), even though the stock has rallied to $90. The 30% premium on the convertible saved 4.6M shares of dilution, worth roughly $410M at current prices.

A mandatory convertible must convert into common stock at maturity, regardless of stock price. The investor has no choice to hold the bond to maturity for repayment of principal.

Differences from a regular convertible:

No bond floor protection. Mandatory holders are exposed to equity downside; if the stock crashes, conversion happens anyway and they get equity at the depressed price. Higher coupon. To compensate for the lack of optionality, mandatory coupons are typically 5 to 8% (vs 0 to 3% on regular converts). Equity treatment for credit-rating purposes. Rating agencies treat mandatories as equity capital, which is why issuers reach for them when straight-equity dilution would be too painful but they need to support credit ratings (e.g., post-acquisition deleveraging where the issuer needs to demonstrate equity capital).

Common features: dual conversion ratios (a higher ratio if stock is below an upper threshold and a lower ratio if above) creating an embedded long-collar payoff, and 3-year typical maturity.

Two scenarios drive mandatory issuance.

Rating-agency optics. The company needs equity capital to support its credit rating after a deleveraging event or a large debt-funded acquisition. Issuing straight common dilutes management/insider ownership and signals weakness; issuing a mandatory delivers equity-rated capital without that signaling, with conversion deferred 3 years.

Dilution timing. Management believes the stock is currently undervalued and doesn't want to issue at today's price. A mandatory effectively pre-sells equity to investors at today's price (or at a small premium via the dual-conversion-ratio structure) but defers actual share issuance for 3 years. If the stock rallies in those 3 years, the conversion ratio steps down and dilution is reduced.

The classic precedent: post-acquisition mandatory issuance by industrial and financial issuers rebuilding balance-sheet equity. AT&T's mandatory in the 2000s telecom era is the textbook example.

An exchangeable bond is a bond issued by Company A but exchangeable into shares of Company B (typically because Company A owns a stake in Company B and wants to monetize it).

Mechanics are similar to a regular convertible (par, coupon, conversion premium) but the conversion is into a third-party stock. Company A's bondholders have the option to convert into Company B shares.

Use case: an industrial conglomerate (Company A) holds a meaningful equity stake in a publicly traded subsidiary or investee (Company B). Company A wants to monetize that stake but selling it directly creates immediate tax recognition and price-impact pressure on Company B. An exchangeable bond lets Company A:

(1) Raise cash today at a low coupon (because the embedded option has value). (2) Defer the sale of Company B shares for 5 to 7 years. (3) Lock in monetization at a 20 to 40% premium to current Company B price. (4) Defer tax recognition until conversion (if structured properly).

Common in Europe and Asia where companies hold cross-shareholdings (e.g., a Japanese keiretsu unwinding stakes via exchangeable bonds).

A PIPE (Private Investment in Public Equity) is a private placement of equity (or equity-linked) securities by an already-public company, sold to a select group of accredited or institutional investors without a public offering.

Differences from a public follow-on:

Private placement, not public. No SEC registration process upfront, no roadshow, no underwriter book-build. Shares are sold directly to a defined group of institutional buyers.

Resale registration. Shares typically come with a covenant requiring the issuer to register them for resale within 30 to 90 days post-closing. Until registered, shares are "restricted" and can only be sold under Rule 144 with volume limits.

Speed. PIPEs can close in 2 to 4 weeks with negotiated terms, vs the longer process for a marketed public offering.

Pricing. PIPEs price at a discount to current stock (typically 5 to 15%), reflecting the illiquidity of restricted shares plus the negotiated nature.

Use cases: smaller-cap companies needing capital quickly, situations where issuer wants to bring in strategic or anchor investors, distressed or special-situation financings, and SPAC backstop financings.

Rule 144A is an SEC rule that permits resales of unregistered securities to Qualified Institutional Buyers (QIBs) without the typical Rule 144 holding-period restrictions. A QIB is generally an institution that owns and invests at least $100M in securities.

A 144A convertible offering is structured as: issuer privately places convertible bonds with initial purchasers (typically the underwriting banks), who immediately resell to QIBs under the 144A safe harbor. The convertibles are not SEC-registered for primary issuance, but their resale into the institutional market is permitted.

Why convertibles use this format:

Speed. No SEC review of registration statement; the deal can launch and price the same day. Convertibles often launch after market close and price overnight, executing in 24 to 48 hours.

Investor base. Convertible buyers are predominantly institutional (mutual funds, hedge funds doing arb, dedicated convert funds). They are nearly all QIBs, so the 144A audience reaches the natural buyer base.

Disclosure. 144A offering memoranda are similar to public prospectuses in disclosure depth, so QIBs get adequate information without the SEC review delay.

Most US dollar-denominated convertible issuance over the past two decades has been done as 144A offerings.

Two main investor types.

Outright (long-only) convertible buyers. Dedicated convertible mutual funds (Calamos, Allianz, AB), multi-asset funds, balanced portfolios. They buy convertibles for the asymmetric payoff: bond-floor downside protection plus equity-call upside, with risk-adjusted returns historically competitive with equities.

Convertible arbitrage hedge funds. They buy the convertible and simultaneously short the underlying stock, aiming to be delta-neutral (insensitive to small stock moves). The trade earns profits from: (1) the coupon, (2) gamma (rebalancing the short hedge as the stock moves captures volatility), (3) convergence to fair value (mispricing in the option), and (4) credit spread tightening.

Approximate breakdown: roughly 50 to 60% of convertible demand is outright, 40 to 50% is arb, with the mix shifting between cycles. Arb activity surges when implied vol is rich and credit spreads are tight (good entry economics for the arb trade).

Three differences.

(1) Comps anchor IPO; precedents and DCF anchor M&A. IPO valuation primarily uses public-company trading multiples, because IPO investors are deciding to buy this stock vs other names in the public market. M&A valuation gives more weight to precedent transaction multiples (recent comparable deals at control premiums) and DCF intrinsic-value analysis.

(2) IPO pricing has a 10 to 20% discount; M&A has a 20 to 35% control premium. IPOs price below intrinsic value to incentivize investor participation and aftermarket success. M&A buyers pay above public-market value to gain control. So a company that IPO's at $50 implying a $5B equity value would likely sell at $7B+ to a strategic buyer for the same fundamentals.

(3) IPO uses post-money equity value; M&A uses fully-loaded enterprise value. IPOs conventionally express valuation per-share at the offer price (ignoring control premium). M&A values are quoted on enterprise-value basis with synergies and capital-structure adjustments built in.

The implication for the issuer: in dual-track processes, an IPO valuation and an M&A bid for the same company can differ by 30 to 50%, with M&A usually higher. That gap is what a banker monetizes by running both tracks.

From low to high in normal markets:

Trading comps < DCF < precedent M&A transactions.

Why. Trading comps reflect public-market clearing prices for minority stakes, with the IPO discount (10 to 20%) layered on top when used to set an IPO price range. DCF estimates intrinsic value without the public-market liquidity discount and without a control premium, so it typically lands above trading comps. Precedent M&A transactions include a control premium (20 to 35%) plus synergy pricing built into the headline, so they sit above DCF.

Hot-market inversion. This ordering can flip. In sectors with extreme demand (AI infrastructure, certain biotech windows), trading comps trade at premiums above any reasonable DCF and above recent M&A precedents. The 2020 to 2021 SaaS market and the 2024 to 2025 AI-infrastructure window are both examples. When that inversion appears, bankers treat trading comps as the primary anchor and use DCF as a sanity check, while precedent M&A loses informational value because deals happened at much lower multiples than current public-market clearing.

For ECM specifically. IPO valuation uses trading comps as the primary anchor, with DCF as a cross-check and precedent IPOs (recent IPOs in the same sector, not precedent M&A) as a directional reference. Precedent M&A is more relevant for dual-track processes where the M&A bid serves as a comparison point against the IPO valuation.

Base implied EV: $200M × 8 to 10 = $1.6B to $2.0B.

Growth-adjusted view: the company is growing 35% vs peers' 25%, a 10 percentage-point premium. Markets typically reward growth differential roughly linearly in EV/Revenue (rule of thumb: every 5 percentage points of growth differential = roughly 1 turn of EV/Revenue, though this varies by sector and rate environment).

Adjusted multiple: apply a 1.5 to 2 turn premium to the comp range = 9.5 to 12x EV/Revenue.

Adjusted EV range: $200M × 9.5 to 12 = $1.9B to $2.4B.

Cross-check: EV/Forward-revenue per 1% of growth = 0.27x to 0.34x for the company, vs 0.32x to 0.40x for peers. Looks reasonable (slightly more conservative than peer growth-adjusted multiples, leaving room for IPO discount).

The IPO would then price the bookbuild range at 15% below this, so $1.6B to $2.0B equity value range, which translates to a per-share offer-price range based on shares outstanding.

Three issues.

(1) Stock-based compensation accounting. EBITDA addbacks for SBC inflate near-term margins for software and growth companies. Investors increasingly look at "cash EBITDA" or EBITDA minus SBC. Ignoring SBC overstates true cash generation.

(2) Capex intensity differences. Two companies with the same EBITDA can have wildly different cash flows if one is capital-intensive and the other is not. EV/(EBITDA − Capex) or EV/UFCF is a cleaner proxy.

(3) Growth distortion. Pure EV/EBITDA doesn't reward growth differentials, so a 30%-growing company and a 5%-growing company in the same sector can look misleadingly similar on the multiple. Adjusted multiples or DCF cross-check are required to normalize.

Strong IPO valuation practice uses EV/EBITDA as the headline metric where appropriate, but always cross-checks with EV/Revenue, growth-adjusted views, and EV/UFCF or DCF to confirm.

Step 1: peer multiple adjustment. Median peer multiple = 8x. Growth differential = -5pts (25% vs 30%). Apply 0.8x adjustment factor: 8x × 0.8 = 6.4x EV/Revenue.

Step 2: enterprise value. $300M × 6.4 = $1.92B.

Step 3: equity value (no net debt). $1.92B = $1.92B.

Step 4: pre-money equity value with IPO discount. $1.92B × (1 − 0.15) = $1.632B.

Step 5: per-share fair-discount price. $1.632B / 100M = $16.32 per share.

Step 6: new shares issued for $500M raise. $500M / $16.32 = 30.64M new shares.

Step 7: post-IPO share count. 100M + 30.64M = 130.64M.

Step 8: IPO file range. Typical bank file range is roughly 10% wide. At midpoint $16.32, file at $15 to $17.50, with the bookbuild deciding final price within (or above/below) that range.

Sanity check on post-money valuation: $16.32 × 130.64M = $2.13B post-money equity, which is the pre-money $1.632B plus the $500M raise = $2.132B. ✓

Start broad (15 to 20 candidates) using GICS classification, sector research coverage universes, S-1 self-identified peers, and industry databases. Then filter on:

Business model match. Same revenue model (subscription vs transactional vs licensing), same customer type (B2B vs B2C vs both), similar product category. Size match. Similar revenue and market cap range; comparing a $5B issuer to $50M and $50B peers is noisy. Growth match. Similar growth rates; a peer growing 5% prices very differently from one growing 30%. Margin match. Similar gross-margin and EBITDA-margin profile. Geography/regulation match. Same primary market and regulatory regime where it materially affects unit economics.

After filtering, end with 5 to 10 peers for the formal comp set, ideally split into "core" peers (most directly comparable, cite as primary) and "broader" peers (extended universe for context).

A bad peer set has too few comps (no statistical signal), too many heterogeneous comps (median is meaningless), or peers that are mid-cycle in different positions (one in expansion, one in turnaround).

Three reasons.

Sanity check on peer-multiple reasonableness. If comps imply a $50/share offer price and DCF (with reasonable assumptions) implies $30 to $40, something is wrong: either the comps are mispriced or the assumptions are off. The investigation surfaces issues before pricing.

Defending valuation to management and the board. "The comps say $50; the DCF cross-check supports $45 to $55 with reasonable assumptions" is a much stronger pricing recommendation than a single-method point estimate. Boards want triangulation.

Investor questioning during the roadshow. Sophisticated investors will ask "what does your DCF say?" and have built their own. Bankers need to be able to defend the relationship between comp valuation and DCF, particularly in sectors where DCF is non-standard (early-stage biotech rNPV, software with growing TAM).

DCF's role is supportive, not decisive. The primary number remains comp-driven.

Yes, but the relevant precedent set is precedent IPOs, not precedent M&A transactions.

Precedent IPOs (recent IPOs in the same sector, ideally within the past 12 to 24 months) are the closest analog to the deal being priced. They show how the market actually clears for similar businesses going through the same primary-issuance discount mechanism. Bankers track precedent IPO multiples, IPO discounts applied, first-day performance, and 30-day post-IPO performance to calibrate the current pricing.

Precedent M&A transactions are typically a poor primary anchor for IPO valuation because they include a control premium (20 to 35%) and often synergy pricing baked into the headline. Applying M&A multiples to an IPO would dramatically overprice the deal, since IPO investors do not pay control premia. Precedent M&A is useful only as a directional ceiling check: in a dual-track process, an M&A bid above the IPO valuation tells you what a strategic would pay for control, which is the comparison point for choosing between paths.

Practical hierarchy for IPO valuation.

1. Trading comps (primary anchor): public peers' EV/Revenue or EV/EBITDA, applied to the issuer's forward financials with the IPO discount layered on top. 2. Precedent IPOs (directly relevant precedent): how recent comparable deals priced, what discount was applied, how they traded. 3. DCF (cross-check): does the multiple-implied valuation make sense at reasonable cashflow assumptions? 4. Precedent M&A (ceiling check, dual-track only): what would a strategic pay for control?

A strong IPO pricing recommendation triangulates all four, with trading comps and precedent IPOs as the dominant inputs.

Three reasons that overlap.

(1) Demand certainty. IPOs need oversubscribed books to clear cleanly. A 15% discount creates the cushion that makes investors willing to commit at the bookbuild stage. Without it, demand would be tepid and pricing would slip.

(2) First-day pop optics. Issuers (and their bankers) want a first-day price increase as a marketing signal. A 10 to 15% pop validates the deal, attracts research coverage, and creates positive PR for the company and its banks. Without underpricing, the average IPO would trade flat or down on day one and the franchise damage would compound across deals.

(3) Compensation for information asymmetry. Investors buying an IPO have less information than the issuer and its bankers, and bear new-listing risk (no public trading history). The discount compensates them for that risk. Higher-quality bankers (with stronger reputations) can price closer to fair value because their certification reduces the information-risk premium investors require.

In normal markets the discount is 10 to 15%. In hot markets (where investor demand is robust) it can compress to 5 to 10%. In weak markets it widens to 20%+.

Discounted equity value used for IPO pricing: $10B × (1 − 0.15) = $8.5B.

Pre-IPO equity at discount: $8.5B based on 200M shares pre-IPO = $42.50/share.

At $42.50 offer price, primary 30M shares raise: 30M × $42.50 = $1.275B in primary proceeds.

Post-IPO share count: 200M + 30M = 230M shares.

Post-IPO equity at offer price: 230M × $42.50 = $9.775B (equals pre-IPO discounted equity $8.5B + primary $1.275B = $9.775B). ✓

At fair value pricing ($10B / 200M = $50 pre-IPO): - Same $1.275B raise would require: $1.275B / $50 = 25.5M new shares (vs 30M at IPO discount). - Post-fair-value share count: 200M + 25.5M = 225.5M. - Post-fair-value equity: 225.5M × $50 = $11.275B.

Difference in dilution: at IPO-discount pricing, 30M new shares (13% dilution); at fair-value pricing, 25.5M new shares (11.3% dilution). Issuer suffered 4.5M extra shares of dilution (worth roughly $225M at fair value) to access the discounted IPO market.

Conclusion: the 15% IPO discount cost the existing shareholders ~$225M of value (the foregone dilution). This is the implicit cost of going public via underwritten IPO vs theoretical at-fair-value pricing. The cost is justified (in normal markets) by the certainty, broad distribution, and long-term institutional ownership the IPO process delivers.

Three reasons it persists.

(1) Information asymmetry. Bankers don't know exactly where the stock will trade once it's free. They observe demand at the file price range and infer interest, but the post-listing price discovery includes natural-buyer demand that isn't captured pre-listing. Pricing at fair value risks pricing too high if some of the demand was opportunistic flipper interest.

(2) Allocator economics. IPO allocations are a banker tool to reward and retain quality institutional investors. If IPOs always priced at fair value, allocations would have no economic value and the entire allocation system would lose its bargaining utility.

(3) Reputational economics. A failed IPO (priced and trades down) damages the bank's franchise far more than a deeply oversubscribed deal with an underpriced offer does. The asymmetry of consequences pushes bankers toward pricing conservatively.

Academic research (Loughran/Ritter) attributes the persistence of underpricing to "issuer indifference" caused by behavioral framing: issuers experience a successful IPO with a pop as a win, even though it left capital on the table.

New shares: 10M (raised at $30 = $300M).

Post-deal share count: 100M + 10M = 110M.

Interest savings: $300M × 6% = $18M pre-tax = $18M × (1 − 25%) = $13.5M after-tax interest savings.

Pro-forma net income: $200M + $13.5M = $213.5M.

Pro-forma EPS: $213.5M / 110M = $1.94.

Standalone EPS was $2.00; pro-forma is $1.94. The deal is dilutive to EPS by 3.0%.

Why it's dilutive: the new equity is being issued at an earnings yield of EPS / price = $2 / $30 = 6.67%, while the after-tax cost of the debt being repaid is 6% × (1 − 25%) = 4.5%. Since 6.67% > 4.5%, the company is funding the swap at a higher cost than the debt it's paying off, so the deal is dilutive.

Breakeven analysis: to be neutral, raise price would need to be where new EPS = $2.00. Solve: $213.5M / X = $2.00 → X = 106.75M total shares → 6.75M new shares. New shares × price = $300M → price = $300M / 6.75M = $44.44.

So the deal would need to price at $44.44 (vs $30) to be EPS-neutral. At $30, it is dilutive.

Long-only mutual funds: Fidelity, Wellington, T. Rowe Price, Capital Group, Vanguard. Buy IPOs to add to actively managed funds. Hold for 3 to 5+ years if thesis works. Most desirable allocation recipients.

Pension and endowment funds: Cal-PERS, ABP, Yale, Harvard. Long-duration capital, slow-moving, conservative. Buy IPOs through external managers or directly for large deals.

Sovereign wealth funds: GIC, Temasek, ADIA, QIA, NBIM. Very long-duration capital. Anchor or cornerstone roles in large IPOs (especially Asian deals) for size and signaling.

Hedge funds: mixed quality. Long/short equity hedge funds (Lone Pine, Coatue, Tiger Global affiliates) can be quality fundamental investors. Event-driven and fast-money flippers are typically allocated under-weight relative to demand because they sell day-1.

Index funds: don't participate in IPOs directly; must wait until the stock is added to the relevant index, which can be months or quarters post-listing.

Retail investors: typically allocated 10 to 15% of the deal through participating brokers' retail allocations. Provides supportive but not deep aftermarket demand.

The "ideal" allocation profile is 60 to 70% long-only mutual funds and pension funds, 10 to 20% sovereigns and anchors, 5 to 15% retail, and the remainder to high-quality hedge funds.

Three reasons.

(1) Size capacity. SWFs (GIC managing roughly $800B, Temasek roughly $400B, ADIA roughly $700B+, QIA, NBIM at $1.7T+) can take large allocations in single IPOs. A $100M to $500M anchor commitment from one SWF can stabilize a multi-billion-dollar deal.

(2) Long-duration holding. SWFs invest with multi-decade horizons. Their participation signals long-term confidence and supports aftermarket stability. A SWF in the deal is unlikely to flip day-1.

(3) Validation and PR. A confirmed SWF anchor (especially GIC, Temasek, NBIM) creates a positive signaling effect that draws other investors into the book. The bank can market the deal as "GIC has committed $200M as anchor."

The trade-off: SWFs are price-sensitive in their own ways. They negotiate hard on allocation, may demand pricing concessions, and can withdraw if the deal terms shift. Bankers manage SWF relationships across many deals over years.

A cornerstone investor in an Asian IPO (especially HKEX, Singapore, India) is a pre-committed buyer who agrees in advance to subscribe for a defined dollar amount of shares at the IPO price, in exchange for a guaranteed allocation and public disclosure of their participation.

Cornerstones are disclosed in the prospectus. They typically subscribe for 30 to 60% of an Asian IPO's offering size. The lockup is 6 months standard.

In contrast, US anchors are also pre-committed but typically not publicly disclosed (or only generically described). They get priority allocation but don't have explicit guaranteed dollar amounts disclosed in the S-1.

The Asian cornerstone model exists because Asian retail demand is volatile and prone to "underwriting failure" without anchor commitments. Cornerstones provide price-clearing certainty. They also serve as a brand-validation signal for retail investors who follow institutional names.

In 2025 HKEX deals, BlackRock, GIC, Temasek, Hillhouse, and major mainland-Chinese investors have been active cornerstones. The structure has become a feature of HK's competitive position vs other Asian listing venues.

Total deal size: HKD 8B / HKD 100 per share = 80M shares offered.

Cornerstone shares: HKD 4.5B / HKD 100 = 45M shares (locked for 6 months).

Public allocation: 80M − 45M = 35M shares.

Public oversubscription: 25x means HKD 3.5B × 25 = HKD 87.5B of public demand chasing 35M shares. Allocation cuts: each public order gets ~4% of order size.

Day-1 free float: 35M shares (cornerstones locked).

Pre-IPO holders' shares: depends on issuer cap table; if the IPO is 20% of post-IPO equity, then total post-IPO shares = 80M / 0.20 = 400M shares, meaning pre-IPO insiders hold 320M shares (also typically locked).

Day-1 free float as % of total: 35M / 400M = 8.75%.

Implication: the small free float (8.75%) creates inherent supply scarcity and supports the post-listing price during the lockup period. When cornerstones unlock at month 6, an additional 11.25% of supply enters the market, often pressuring the stock if cornerstones rotate out.

This is the structural reason HK IPOs often trade strongly post-listing (high cornerstone + insider lockup share, low float) and dip into the 6-month cornerstone unlock.

Empirical work (Chen and Ritter, "The Seven Percent Solution") found that 94% of US IPOs between $20M and $100M priced with a 7% gross spread. The number is convention more than economics: bookrunners coordinate to maintain the standard, deviation gets punished by lost mandates, and issuers don't have strong incentive to negotiate down because the underwriting market lacks price competition for mid-cap IPO mandates.

For larger IPOs (>$1B), spreads compress to 4 to 6% because absolute fee dollars become large enough that issuers negotiate harder, and some banks differentiate on price to win mandates. For very large mega-IPOs ($5B+), spreads can compress to 3 to 4%.

For sub-$50M IPOs (smaller exchanges, microcap underwriters), spreads can rise to 8 to 10% because underwriting risk per dollar of capital is higher.

The 7% is sometimes described as "the lawyer's bill plus the stockbroker's commission." Critics call it cartel-like; defenders say the consistency reflects the standard cost structure of running a bookbuild and underwriting commitment for a mid-sized deal.

Total gross spread: $250M × 7% = $17.5M.

Buckets: - Management fee: $17.5M × 20% = $3.5M - Underwriting fee: $17.5M × 20% = $3.5M - Selling concession: $17.5M × 60% = $10.5M

Lead-left share: - Management: $3.5M × 50% = $1.75M - Underwriting: $3.5M × 35% = $1.225M - Selling concession: $10.5M × 45% = $4.725M

Total lead-left economics: $1.75M + $1.225M + $4.725M = $7.7M, which is 44% of the total fee pool.

The lead-left's outsized share (44% on this deal) compared to its 50%/35%/45% allocation per bucket reflects the heavier weighting toward selling concession (60% of the pool) and lead-left's strong selling-concession allocation.

A+H means a Chinese company is listed both on a mainland Chinese exchange (Shanghai or Shenzhen, A-shares in RMB) and on the Hong Kong Stock Exchange (H-shares in HKD). The first A+H was Tsingtao Brewery (1993); by 2025 there were roughly 150 A+H companies.

Why list in HK from mainland (the "China-to-HK pipeline"):

(1) International capital access. A-shares are restricted to mainland investors (with limited Stock Connect access). H-shares trade on a fully open international market, giving the company access to USD-denominated foreign capital.

(2) Currency diversification. USD/HKD-denominated capital provides FX flexibility for international expansion.

(3) Visibility and benchmark inclusion. HK-listed Chinese companies enter HSI/HSCEI, MSCI EM, FTSE benchmarks more readily than A-shares. Index inclusion drives passive demand.

(4) Liquidity for offshore expansion. Cross-border M&A and offshore acquisitions are easier with HKD-listed equity as currency.

The "AH premium" phenomenon: the same company's A-shares typically trade at a meaningful premium to H-shares (15 to 50% historically). The premium reflects mainland market segmentation (capital-control restrictions limit arbitrage), retail-driven A-share volatility (80% of A-share investors are retail), and different valuation conventions. The 2025 CATL listing was notable for pricing H-shares at a premium to A-shares, a rare structural inversion.

An American Depositary Receipt is a US-listed security representing a foreign company's stock. The mechanism: a US depositary bank (BNY Mellon, Citi, JPMorgan, Deutsche) holds the foreign shares with a custodian, then issues USD-denominated ADRs that trade on US exchanges. ADRs settle in US clearing systems and trade on US time, allowing US investors to own foreign companies without dealing with cross-currency transactions or foreign settlement.

ADR levels:

Level 1 (lowest): OTC-traded only. No SEC registration; minimal disclosure (the foreign company posts annual reports per home-country rules in English on its website). Low cost, low liquidity. Commonly used for dipping a toe in US markets.

Level 2: Listed on NYSE/Nasdaq. SEC registration required (Form 20-F annually, not Form 10-K). No primary capital raise (the foreign company doesn't issue new shares).

Level 3 (highest): Listed on NYSE/Nasdaq with primary capital raise via the US market. Full SEC registration, full reporting, compliance with US securities laws. Used by foreign companies that want to raise US capital and access broad US institutional investors. Most prominent foreign issuers (TSMC, ASML, Alibaba) use Level 3.

Rule 144A ADRs: sold to QIBs only via Rule 144A; no public listing required, lighter disclosure. Used by foreign issuers wanting institutional US capital without full Level-3 burden.

A Global Depositary Receipt is the international cousin of an ADR. GDRs typically trade on London (LSE) or Luxembourg and are sold to investors in two or more markets outside the issuer's home country, usually under Rule 144A and Regulation S.

Differences:

Listing venue. ADRs trade on US exchanges; GDRs primarily on LSE/Luxembourg.

Investor base. ADRs reach US institutions and retail. GDRs reach European and Asian institutional investors.

Regulatory regime. ADRs are subject to SEC and US-exchange rules. GDRs operate under home-country issuer rules with overlay of LSE or Luxembourg rules and any 144A disclosure requirements.

Use cases. Indian, Russian (pre-sanctions), and CIS issuers historically heavy GDR users to access European capital. Some issuers do both (ADRs for US, GDRs for Europe) for broader cross-border distribution.

Five factors.

(1) Investor base. US (NYSE/Nasdaq) has the deepest institutional base globally, particularly for tech and software. HKEX has strong Asian institutional and Chinese mainland investor access via Stock Connect. LSE has European institutions and is well-suited for resource-sector and consumer issuers.

(2) Sector fit. Nasdaq dominates tech, biotech, growth (50%+ of US tech IPOs since 2010). NYSE is preferred for mature industrials, consumer brands, financials. HKEX for China and Asia-Pacific. LSE for resources, financials, and European consumer.

(3) Valuation. US listings generally achieve higher trading multiples than non-US for tech/growth companies (the "US premium" is real, 20 to 40% vs European/Asian listings for comparable software businesses). HKEX is roughly comparable for Chinese issuers vs A-share peers (post-AH premium adjustment).

(4) Listing cost. Nasdaq is cheaper than NYSE for ongoing fees (max annual fee $193K vs $500K). HKEX and LSE have their own fee structures, generally lower than NYSE.

(5) Regulatory regime. US has the most stringent ongoing disclosure (SOX, Reg FD). UK/EU have lighter ongoing disclosure (UK 2024 reforms moved closer to a US-style disclosure regime). HKEX is in between.

Practical pattern: US-based issuers default to Nasdaq (tech) or NYSE (others). Chinese issuers default to HKEX with optional secondary US listing. European issuers list locally with optional US ADRs for global growth companies. Israeli companies often go directly to Nasdaq. Indian companies historically used GDRs in LSE; recently more direct US listings via Mauritius structures.